NICE MEDICAL TECHNOLOGY GUIDANCE RECOMMENDS URGOSTART TREATMENT RANGE
Recently published NICE guidance recommends the use of UrgoStart on Venous Leg Ulcers and Diabetic Foot Ulcers(1)
UrgoStart dressings are proven to reduce healing time for patients, improving patients' quality of life, and are associated with significant cost savings for the NHS compared to non-interactive dressings.
What does the NICE medical technology guidance say about UrgoStart Treatment Range?
Reduces healing time
UrgoStart Treatment Range heals wounds sooner
UrgoStart is clinically proven to reduce healing time through the highest level of evidence (2-5)
UrgoStart with its TLC-NOSF* Healing Matrix has a unique mode of action to reduce healing time: inhibition of matrix metalloproteinases and promotion of angiogenesis (5,6)
£342 per patient per year for diabetic foot ulcers(1)
£541 per patient per year for leg ulcers**(1)
Reducing healing time can save money through:
Reduced use of current dressings in managing wounds
Reduced risk of infection and associated complications
Fewer community nursing and hospital visits
Easy to implement
UrgoStart can be easily incorporated into current care pathways as part of the standard of care
UrgoStart treatment range does not require any specific training to be used in clinical practice
Enhances quality of life
UrgoStart improves the quality of life for patients
Reducing healing time with UrgoStart significantly reduces pain/discomfort and anxiety/depression (4)
** Results from the NICE External Assessment Centre (EAC) base case analysis
NICE medical technology guidance 42: UrgoStart for treating diabetic foot ulcers and leg ulcers, https://www.nice.org.uk/guidance/mtg42; accessed August 2019
Münter KC, Meaume S, Augustin M, Senet P, Kérihuel J.C. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153
Meaume S, Truchetet F, Cambazard F et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.
Meaume S, Dompmartin A, Lazareth I, Sigal M, Truchetet F, Sauvadet A, Bohbot S. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.
Edmonds M, Lázaro-Martínez JL, Alfayate-García JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piaggesi A. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
White, R., Cowan, T., Glover, D. Supporting evidence-based practice: a clinical review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London, 2015.